Amarin Corp Plc (AMRN)

[biowreck]

Nick...this dilemma regarding backdoor to reduce it patient population by the generics was always a concern to me because vascepa is the same drug for both Indications (marine and reduce it). So it appears the only strategy the company had to fend off competition was thru patents? What if patents failed...as happened regardless of Judge Du’s opinion (which by the way is a bitter pill to swallow that one opinion can do this much damage). Management had no backup plan for the anchor spa in 2013 either which pissed me off. Business 101...always have a backup plan if the answer is NO!